Trial Profile
A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Idelalisib (Primary) ; Ricolinostat (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 13 Jun 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2026.
- 13 Jun 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2024.
- 10 May 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2022.